To investigate the effect of viral inoculation by adenovirus 5 (Ad5) on body composition in a mouse model. DESIGN: Longitudinal monitoring before and after a single injection of virus or saline. SUBJECTS: Two groups of CD1 mice, one group given a single intraperitoneal dose of Ad5 and the control group, saline. MEASUREMENTS: Bodyweights and food intake were recorded before and up to 21 weeks after inoculation. At the end of the study, whole-body 1 H magnetic resonance spectroscopy (MRS) and localised in vivo 1 H MRS spectroscopy of the liver was performed to assess whole-body adiposity and intrahepatic lipid content, respectively. RESULTS: Ad5-treated animals gained significantly more weight over a period of 21 weeks after inoculation than the controls, 21.8 g (18.8-25.0) and 18.8 g (17.3-19.8) respectively, (Po0.05). The gain in bodyweight in the former animals arises from increased deposition of adipose tissue as measured by whole-body 1 H MRS. Adiposity was 6.7% (3.10-11.20%), and 2.40% (0.85-5.65%) for the Ad5-treated and control animals, respectively (Po0.05). No significant difference in intrahepatic lipid content or food intake was observed between the two groups. CONCLUSION: The significantly higher percentage of adipose tissue in the Ad5-treated mice suggest viral infection may play a contributory role to a predisposition to obesity, although its contribution relative to other factors remains to be determined.
Introduction
The prevalence of obesity has dramatically increased worldwide. The mechanism associated with the development of obesity is not fully understood, although it seems to be associated with a multitude of factors, including neural, endocrine, genetic and environmental. 1 Obesity potentially arising from viral infection, 'infectobesity', has largely been overlooked. Increased adiposity has been observed in animal models following infection with animal viruses, canine distemper virus, [2] [3] [4] [5] Rous-associated virus, 6, 7 Borna virus, 8 an avian adenovirus, SMAM-1 9, 10 and, also, with the human virus adenovirus 36 (Ad36). [11] [12] [13] Of these, SMAM-1 and Ad36 have been associated with human obesity: increased level of antibodies for these viruses has been found in human subjects who were obese. 14, 15 Ad36 produces a syndrome of visceral obesity in chickens and mice, both hyperplastic and hypertrophic in nature. 16 Ad36 is one of many serotypes of human adenoviruses that have been identified, distinguished on the basis of cross-neutralisation tests. The serotypes are classified into subgenus A-F, with Ad36 belonging to subgenus D. Adenoviruses belonging to subgenus A induce tumours with high frequency and short latency, those belonging to subgenus B are weakly oncogenic, whereas those from subgenus C, D, E and F are nononcogenic. Adenovirus 5 (Ad5) belonging to subgenus C has been extensively studied, and genetically modified forms of Ad5 have been proposed as candidate vectors for gene therapy. 17 However, the potential side effects of such vectors have not been fully investigated.
In vivo

1
H magnetic resonance spectroscopy (MRS) has been recently proposed as a rapid and noninvasive method to determine body composition in mice. 18 This technique has been shown to correlate well with data obtained by chemical dissection analysis when applied to the assessment of wholebody adiposity, 18 thus allowing sequential measurements to be carried out. In this study, we have investigated the effects of Ad5 on body adiposity in a murine model. , and then were weighed prior to killing. All animals were given access to food and water at all times except prior to scanning, before which they were fasted for 16 h.
Materials and methods
Animals and treatment
Ad5 preparation
The Ad5, a lab-adapted strain, was obtained from Cancer Research UK. The virus was propagated on 293 cells, harvested by freeze/thaw and purified by double caesium chloride gradient ultracentrifugation. Whole-body 1 H MRS data were processed using SPECNMR (JEOL, USA) software. An exponential line broadening of 5 Hz was applied to the data prior to Fourier transformation and the resultant spectra referenced to the water resonance at d4.8 ppm. After baseline correction of the spectra, the water and lipid resonances were integrated. The percentage adiposity was calculated according to equation (1) , assuming the fat-free mass is 0.38 times that of the water measured: 18, 19 % adiposity ¼ 100ÂI ðlipidÞ I ðlipidÞ þ I ðwaterÞ þ 0:38ÂI ðwaterÞ ð1Þ
MR measurements
I (lipid) and I (water) are integrals for lipid and water, respectively.
The localised 1 H MR spectra of the liver were processed with MestRE-C freeware program (Santiago de Compostela, Spain; www.mestrec.com). The data were Fourier transformed following zero-filling to 16 K and application of an exponential line broadening of 5 Hz. The relative ratio of water to intracellular hepatic lipids was determined by integration of the water and lipid peaks after baseline correction and referencing the water peak to d4.8 ppm.
Data analysis
All values are quoted as median (interquartile range) and statistical analysis performed using SPSS (SPSS Inc., Chicago, USA). The Mann-Whitney test was used to test for differences in percentage adiposity and bodyweights between the control and Ad5 groups.
Results
Bodyweight and food intake data Prior to treatment, no significant differences in bodyweight were observed between the two groups, being 14.8 g (13.0-16.3 g) and 13.5 g (13.0-15.8 g) for the control and Ad5 groups, respectively (Table 1) . After 21 weeks, the Ad5-treated animals acquired more weight than controls (Po0.05, Figure 2 ), the mean weight for Ad5-treated animals was 21.8 g (18.8-25.0), whereas for the controls it was only 18.8 g (17.3-19.8). During this period, food consumption for both groups was similar, with an average cumulative food intake per cage of 4342755 g and 46737193 g for the control and Ad5 groups, respectively. This is the equivalent of 724 g and 779 g per mouse given saline or Ad5, respectively.
Whole-body adiposity Typical whole-body 1 H MR spectra of control-and Ad5-treated animals are shown in Figure 1 , with peaks arising from whole-body water and lipid dominating the spectra. By the end of the treatment period, the percentage adiposity as measured by whole-body 1 H MRS was significantly higher in the Ad5-treated group, 6.7% (3.10-11.20%), compared to controls, 2.40% (0.85-5.65%). Statistical testing indicated that the Ad5 group had higher percentage adiposity (4279%) than the saline-treated group (Po0.05). Taking the upper quartile of the control group (5.65% adiposity) as Adiposity induced by adenovirus 5 inoculation P-W So et al the standard, 66.70% of the Ad5-treated animals was found to have adiposity above this value, compared to only 16.70% of the controls. This clearly represents a substantial increase in the number of animals presenting abnormal adiposity following Ad5 treatment ( Figure 2 ).
Intrahepatic lipid content
In vivo 1 H MRS was utilised to determine intrahepatocellular triglyceride content in control-and Ad5-inoculated animals. No significant difference was observed in levels of intrahepatic lipids between the two groups, the ratio of the water to the lipid peak was 0.94 (0.62-1.59) and 1.69 (0.40-2.28) for the control-and Ad5-treated animals, respectively.
Discussion
In this study, we have shown that inoculation with Ad5, a potential gene-therapy vector, can lead to a significant modulation in the level of adipose tissue content in mice. Animals treated with this adenovirus showed an increase of 4279% in adiposity, compared to controls, with no apparent increase in overall food consumption.
The potential role of viral infection in the pathophysiology of obesity has shown renewed interest in recent years. Infectobesity or increased body adiposity arising from viral infection was first recognised by Dhurandhar et al 10 when
looking at the effects of viral infections on adiposity in chicken. This initial finding has now been extended to other species, including mice, primates, canine and possibly humans, with a range on animal and human viruses, including canine distemper virus, Rous-associated virus 7, Borna disease virus, SMAM-1 and Ad36. [5] [6] [7] [8] [9] [10] [11] [12] [13] In the present study, we have shown that the potential gene therapy viral vector Ad5 also leads to increase body adiposity in mice. Ad5-treated animals were shown to gain more weight over the 21 weeks following inoculation than saline-treated animals. Further, this increase was shown to arise from increased deposition of adipose tissue rather than lean tissue, as evident by the increase in percentage adiposity as measured by whole-body 1 H MRS, similar to that observed by Dhurandhar et al, 11 using Ad36 inoculation and chemical analysis methods. The molecular mechanisms underlying the increase in adiposity in the Ad5-treated animals compared to the salinetreated animals are presently unknown. The results from our study appear to counter the possibility that the increased adiposity arises from increased food intake. As a group, control and inoculated animals showed comparable level of food intake data in this study, similar to that previously reported, 11 suggesting that the viral infection may affect adiposity through other mechanisms besides alterations in appetite and/or satiety. An alternative mechanism recently proposed by Vangipuram et al, 20 is that human adenovirus can enhance preadipocyte differentiation, which in turn could lead to an increase in adiposity. Interestingly, this apparent dysfunction of lipid metabolism, localised to adipose tissue alone, is consistent with the findings in our study, since we did not detect irregular accumulation of lipids in a nonadipose tissue such as the liver. It is of course possible that this adipocyte response may not be specific to Ad5 and that it may arise from infection or inflammatory insult. Indeed, it has been recently suggested that the PPAR-g nuclear receptor, which controls adipocyte differentiation, may also play a pivotal role in anti-inflammatory responses, thus closely linking lipid metabolism and inflammation. 21 It is therefore possible that the increase in adiposity observed in the present study may be a 'side effect' of a generalised anti-inflammatory response to the Ad5 pathogen. 22, 23 Clearly, further work is required to establish the extent that infectobesity arises from adipocyte differentiation and/or inflammatory responses to sustained pathogen exposure and if these changes extend to the distribution of adipose tissue as well as the amount of adipose tissue deposition. The fact that Ad5 virus is a human pathogen raises some potentially intriguing questions. Obesity is clearly a multifactorial disorder with environmental factors making a significant contribution. 1 However, the potential role of pathogens such as viruses in acquired obesity has until now Adiposity induced by adenovirus 5 inoculation P-W So et al been mostly overlooked. The work presented in this study suggests that exposure to human viral pathogens, albeit in a murine model, may actually have a significant impact on whole-body adiposity, either through modulation of food intake and/or as a direct effect on adipocyte function. If similar effects are taking place in human subjects, then the role of these pathogens on adipocyte function should be further investigated, especially if these pathogens can modulate the response of adipocytes to a sustained obesitogenic western diet. Finally, the use of Ad5, albeit replicationincompetent forms, may have significant implications for its role in gene therapy protocols in clinical studies due to the unknown influence Ad5 may exert on lipid metabolism.
In conclusion, we have shown that exposure to Ad5, a human pathogen, can lead to a significant increase in adiposity, independent of food intake in a murine model.
